Quantcast
Last updated on April 23, 2014 at 20:10 EDT

Latest Ampio Pharmaceuticals Inc. Stories

2014-02-13 08:29:59

GREENWOOD VILLAGE, Colo., Feb. 13, 2014 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) today announced preliminary biochemical analysis of samples of synovial fluid drawn from the index knee (treated knee) of a subset of patients who participated in the SPRING study. This synovial analysis, suggested by the FDA, tests the change in expression of signaling and structural proteins that arise from the treatment of the knee with either Ampion(TM) or the saline vehicle...

2014-02-04 08:28:44

GREENWOOD VILLAGE, Colo., Feb. 4, 2014 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) ("Ampio" or the "Company") today announced that the article reporting the results of its initial pivotal clinical trial of Ampion(TM) for the treatment of pain due to Osteoarthritis of the knee (OAK), was published in PLOS ONE, an international, rigorously peer-reviewed, open-access, online publication which covers primary research from any discipline within science and medicine, and is...

2014-01-15 08:28:06

Expected to create approximately 40 new jobs over next two years GREENWOOD VILLAGE, Colo., Jan. 15, 2014 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) held a groundbreaking ceremony on Friday, January 10th to announce the start of construction of its new state-of-the-art manufacturing facility for its lead drug candidate, Ampion(TM), for the treatment of patients afflicted with osteoarthritis of the knee. Located in the Denver Metro area, the facility is expected to be...

2014-01-13 08:27:33

GREENWOOD VILLAGE, Colo., Jan.13, 2014 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) today announced the 500 patient Phase III pivotal trial of Ampion(TM) for the treatment for osteoarthritis of-the-knee (OAK) has received IRB approval and FDA IND clearance and that patients enrollment and treatments have commenced. http://clinicaltrials.gov/ct2/show/NCT02024529?term=ampio&rank=1 (Logo: http://photos.prnewswire.com/prnh/20120516/MM09116LOGO) Dr. Vaughan Clift,...

2014-01-09 08:27:38

ISO certifications position Luoxis for regulatory clearance and commercialization of the RedoxSYS(TM) diagnostic system. GREENWOOD VILLAGE, Colo., Jan. 9, 2014 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) today announced that subsidiary Luoxis has received ISO 13485:2003 certification, an internationally recognized quality standard for medical devices and diagnostics. The company has also earned ISO 9001:2008 certification, a broadly established international quality...

2014-01-06 08:26:22

Research collaborations advance company goal of incorporating RedoxSYS(TM) oxidation-reduction potential platform into clinical practice and broaden the scope of applications in the critical care setting GREENWOOD VILLAGE, Colo., Jan. 6, 2014 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) today announced that subsidiary Luoxis has entered into research agreements with Western Galilee Medical Center (Nahariya, Israel) and the University of Thessaly (Larissa, Greece)....

2013-12-16 08:25:56

Will Provide FDA Compliant cGMP Manufacturing of Ampion(TM), a New R&D Laboratory and Consolidated Operations GREENWOOD VILLAGE, Colo., Dec. 16, 2013 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) today announced the ten-year lease of a multi-purpose facility located in the Denver Tech Center of Colorado. Renovation, beginning in early 2014, will provide commercial scale, FDA compliant, State-of-the Art, GMP manufacturing of Ampion(TM) and an advanced Research and...

2013-12-13 12:23:58

Spin-Off Positions Ampio to Focus on its Core Inflammatory Assets GREENWOOD VILLAGE, Colo., Dec. 13, 2013 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) today announced that it has spun off its sexual dysfunction business into a standalone company called Vyrix Pharmaceuticals, Inc. The new Company is expected to be funded through an initial public offering. (Logo: http://photos.prnewswire.com/prnh/20120516/MM09116LOGO) Vyrix' assets will include Zertane and...

2013-12-03 08:32:40

GREENWOOD VILLAGE, Colo., Dec. 3, 2013 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) today announced the joining of two prominent scientists in the field of molecular biology and stem cell research to its SAB. (Logo: http://photos.prnewswire.com/prnh/20120516/MM09116LOGO) Michael Macaluso, Ampio's CEO, noted "The company is currently advancing three drugs (Ampion((TM)), Optina((TM)) and Zertane((TM))) and one diagnostic device (ORP) through clinical trials and...

2013-12-02 08:31:07

GREENWOOD VILLAGE, Colo., Dec. 2, 2013 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) today announced receipt of FDA correspondence confirming the acceptance of The Spring Study as pivotal and providing guidance for the design of the second and final pivotal trial of Ampion(TM) for the treatment of osteoarthritis of the knee (OAK). (Logo: http://photos.prnewswire.com/prnh/20120516/MM09116LOGO) Dr. Vaughan Clift, Ampio's Chief Regulatory Officer, noted the letter summarized the...